CLINICAL-FEATURES ASSOCIATED WITH TRANSFORMATION OF CEREBRIFORM T-CELL LYMPHOMA TO A LARGE CELL PROCESS

被引:55
作者
GREER, JP
SALHANY, KE
COUSAR, JB
FIELDS, JP
KING, LE
GRABER, SE
FLEXNER, JM
STEIN, RS
COLLINS, RD
机构
[1] VANDERBILT UNIV,MED CTR,DIV HEMATOPATHOL,NASHVILLE,TN 37232
[2] VANDERBILT UNIV,MED CTR,DEPT DERMATOL,NASHVILLE,TN 37232
[3] VANDERBILT UNIV,MED CTR,DEPT PATHOL,NASHVILLE,TN 37232
[4] VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232
关键词
Cutaneous lymphoma; Transformation; T‐cell;
D O I
10.1002/hon.2900080406
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Some patients with cerebriform T‐cell lymphoma (CTCL) undergo morphologic transformation to a large cell lymphoma. From a series of 113 patients with CTCL, 22 patients were identified with transformed CTCL. Stages of involvement at diagnosis were: I (seven), II (four), III (four), IV (seven). Nine patients had transformation at the initial diagnosis while the median time from diagnosis to transformation in the other 13 patients was 16 months (range: 3 months–6 years). Thirteen had transformation extracutaneously: lymph nodes (eight), central nervous system (two), and other extranodal sites (three). T cell markers were identified in all cases; of 15 cases with complete phenotypes, there were eight T‐helper, three T‐suppressor, and four aberrant T phenotypes. Serology for human T‐leukemia virus‐I (HTLV‐I) was negative in eight patients tested. Median survival from diagnosis was 27 months compared to 53 months in 53 patients without transformation (p = 0.003). Despite combination chemotherapy in 12 patients following transformation, median survival after transformation was 12 months and only 7 months with extracutaneous disease. The likelihood of transformation could not be predicted by the initial histology, immunophenotype, or stage of disease. Copyright © 1990 John Wiley & Sons, Ltd
引用
收藏
页码:215 / 227
页数:13
相关论文
共 82 条
[1]  
AQUARSSON BA, 1988, AM J SURG PATHOL, V12, P264
[2]   DEATH DUE TO SPLENIC RUPTURE IN SUPPRESSOR-CELL MYCOSIS-FUNGOIDES - A CASE-REPORT [J].
BENNETT, SR ;
GREER, JP ;
STEIN, RS ;
GLICK, AD ;
COUSAR, JB ;
COLLINS, RD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 82 (01) :104-109
[3]   THE HUMAN TYPE-C RETROVIRUS, HTLV, IN BLACKS FROM THE CARIBBEAN REGION, AND RELATIONSHIP TO ADULT T-CELL LEUKEMIA LYMPHOMA [J].
BLATTNER, WA ;
KALYANARAMAN, VS ;
ROBERTGUROFF, M ;
LISTER, TA ;
GALTON, DAG ;
SARIN, PS ;
CRAWFORD, MH ;
CATOVSKY, D ;
GREAVES, M ;
GALLO, RC .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (03) :257-264
[4]   IMMUNO-CYTOCHEMICAL DETECTION OF LYMPHOCYTE SURFACE-ANTIGENS IN FIXED TISSUE-SECTIONS [J].
BOROWITZ, MJ ;
CROKER, BP ;
BURCHETTE, J .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1982, 30 (02) :171-174
[5]  
BREHMERANDERSSO.E, 1976, ACTA DERM-VENER S, V56, P10
[6]   SEZARY SYNDROME - MALIGNANT PROLIFERATION OF HELPER T CELLS [J].
BRODER, S ;
EDELSON, RL ;
LUTZNER, MA ;
NELSON, DL ;
MACDERMOTT, RP ;
DURM, ME ;
GOLDMAN, CK ;
MEADE, BD ;
WALDMANN, TA .
JOURNAL OF CLINICAL INVESTIGATION, 1976, 58 (06) :1297-1306
[7]   RECOMBINANT LEUKOCYTE A-INTERFERON - AN ACTIVE AGENT IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS [J].
BUNN, PA ;
FOON, KA ;
IHDE, DC ;
LONGO, DL ;
EDDY, J ;
WINKLER, CF ;
VEACH, SR ;
ZEFFREN, J ;
SHERWIN, S ;
OLDHAM, R .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) :484-487
[8]  
BUNN PA, 1979, CANCER TREAT REP, V63, P725
[9]  
BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501
[10]  
CASEY TT, 1986, LAB INVEST, V54, pA10